LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam

Bulletin Express03-06

Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.

The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.

Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148646401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148646401","market":"us","top_or_hot":-1,"title":"LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.</p>\n<p>The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.</p>\n<p>Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-06 19:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.</p>\n<p>The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.</p>\n<p>Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1148646401","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148646401","pubTimestamp":1772796162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药[01513]宣布越南自愿公开要约收购获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.\nThe company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.\nLivzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148646401","isCrawlerRequest":true}